Opioid-Induced Constipation (OIC) - Pipeline Review, H1 2017

Description: Opioid-Induced Constipation (OIC) - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Opioid-Induced Constipation (OIC) - Pipeline Review, H1 2017, provides an overview of the Opioid-Induced Constipation (OIC) (Oncology) pipeline landscape.

Opioids are effective pain relievers, but often have the side effect of constipation. These medicines affect the gastrointestinal tract in a variety of ways. Opioids increase the amount of time it takes to move through the gastric system. They increase non-propulsive contractions in the middle of the small intestine (jejunum) and decrease longitudinal propulsive peristalsis - motions critical to moving food through the intestines. This results in food that fails to travel through the digestive tract. Opioids are also able to partially paralyze the stomach (gastroparesis) so that food remains in the digestive organ for a longer period of time. Additionally opioids reduce digestive secretions and decrease the urge to defecate. Symptoms of OIC include feeling and being sick, tiredness and lethargy, appetite loss, feeling depressed.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Opioid-Induced Constipation (OIC) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Opioid-Induced Constipation (OIC) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Opioid-Induced Constipation (OIC) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Opioid-Induced Constipation (OIC) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III and Phase II stages are 2, 2 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Opioid-Induced Constipation (OIC) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

- The pipeline guide provides a snapshot of the global therapeutic landscape of Opioid-Induced Constipation (OIC) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Opioid-Induced Constipation (OIC) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Opioid-Induced Constipation (OIC) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Opioid-Induced Constipation (OIC) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Opioid-Induced Constipation (OIC) (Oncology).

Reasons to Buy:
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Opioid-Induced Constipation (OIC) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Opioid-Induced Constipation (OIC) (Oncology) pipeline depth and focus of indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents:

Introduction
Opioid-Induced Constipation (OIC) - Overview
Opioid-Induced Constipation (OIC) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Opioid-Induced Constipation (OIC) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Opioid-Induced Constipation (OIC) - Companies Involved in Therapeutics Development
Develco Pharma Schweiz AG
Ironwood Pharmaceuticals Inc
Shionogi & Co Ltd
Sucampo Pharmaceuticals Inc
Synergy Pharmaceuticals Inc
Theravance Biopharma Inc
Opioid-Induced Constipation (OIC) - Drug Profiles
(axelopran sulfate + oxycodone hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
axelopran sulfate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dolcanatide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
linaclotide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lubiprostone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
methylnaltrexone bromide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naldemedine tosylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naloxone hydrochloride PR - Drug Profile

Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize Mu Opioid Receptor for Drug Abuse, Alcohol Addiction and OIC - Drug Profile

Product Description
Mechanism Of Action
R&D Progress

Opioid-Induced Constipation (OIC) - Dormant Projects
Opioid-Induced Constipation (OIC) - Discontinued Products
Opioid-Induced Constipation (OIC) - Product Development Milestones

Featured News & Press Releases

Dec 19, 2016: Shionogi and Purdue Pharma Establish Alliance for Joint U.S. Commercialization of Naldemedine

Sep 07, 2016: Naldemedine Phase III Study Demonstrates Long-Term Safety And Efficacy For The Treatment Of Opioid-Induced Constipation

Jun 06, 2016: Shionogi Announces Acceptance Of New Drug Application In The U.S. For Naldemedine For The Treatment Of Opioid-Induced Constipation

May 23, 2016: Two Naldemedine Phase III Studies Show Consistent Improvement Of Opioid-Induced Constipation

Mar 30, 2016: Shionogi Submits New Drug Applications In Japan And The U.S. For Naldemedine For The Treatment Of Opioid-Induced Constipation

Feb 19, 2016: Naldemedine Phase 3 Study Shows Significant Improvement for Patients with Opioid-Induced Constipation

Nov 30, 2015: Ironwood Reports Positive Top-Line Data from Phase II Trial of Linaclotide in Adult Patients With Opioid-Induced Constipation

Sep 10, 2015: Theravance Biopharma Presents Positive Clinical Data on Fixed-Dose Combination (FDC) of Axelopran (TD-1211) and Oxycodone at PAINWeek

Aug 03, 2015: Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation

Jun 24, 2015: Shionogi Announces That Naldemedine Met The Primary Endpoint In Its First Japanese Phase 3 Study For The Treatment Of Opioid - Induced Constipation In Cancer Patients

May 19, 2015: Phase Iib Data Show Once-Daily Naldemedine Provides Significant Improvement For Patients With Opioid-Induced Constipation

May 15, 2015: Sucampo Announces Clinical Data on Lubiprostone to be Presented at Digestive Disease Week

Mar 30, 2015: Shionogi Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation

Dec 30, 2014: Sucampo Announces Acceptance of New Drug Submission for AMITIZA (lubiprostone) by
Health Canada

Nov 19, 2014: Synergy Pharmaceuticals Announces Positive Results of SP-333 Phase 2 Trial in Patients with Opioid-Induced Constipation

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

- Number of Products under Development for Opioid-Induced Constipation (OIC), H1
- Number of Products under Development by Companies, H1
- Number of Products under Development by Universities/Institutes, H1
- Products under Development by Companies, H1
- Products under Development by Universities/Institutes, H1
- Number of Products by Stage and Target, H1
- Number of Products by Stage and Mechanism of Action, H1
- Number of Products by Stage and Route of Administration, H1
- Number of Products by Stage and Molecule Type, H1
- Opioid-Induced Constipation (OIC) - Pipeline by Develco Pharma Schweiz AG, H1
- Opioid-Induced Constipation (OIC) - Pipeline by Ironwood Pharmaceuticals Inc, H1
- Opioid-Induced Constipation (OIC) - Pipeline by Shionogi & Co Ltd, H1
- Opioid-Induced Constipation (OIC) - Pipeline by Sucampo Pharmaceuticals Inc, H1
- Opioid-Induced Constipation (OIC) - Pipeline by Synergy Pharmaceuticals Inc, H1
- Opioid-Induced Constipation (OIC) - Pipeline by Theravance Biopharma Inc, H1
- Opioid-Induced Constipation (OIC) - Dormant Projects, H1
- Opioid-Induced Constipation (OIC) - Discontinued Products, H1

List of Figures:

- Number of Products under Development for Opioid-Induced Constipation (OIC), H1
- Number of Products under Development by Companies, H1
Number of Products by Targets, H1
Number of Products by Stage and Targets, H1
Number of Products by Mechanism of Actions, H1
Number of Products by Stage and Mechanism of Actions, H1
Number of Products by Routes of Administration, H1
Number of Products by Stage and Routes of Administration, H1
Number of Products by Molecule Types, H1
Number of Products by Stage and Molecule Types, H

Ordering:

Order Online - http://www.researchandmarkets.com/reports/4091158/

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Opioid-Induced Constipation (OIC) - Pipeline Review, H1 2017
Web Address: http://www.researchandmarkets.com/reports/4091158/
Office Code: SC

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Single User</th>
<th>Enterprisewide</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF)</td>
<td>USD 1600</td>
<td>USD 4500</td>
</tr>
<tr>
<td><strong>USD 2000 - Until Jun 02nd 2017</strong></td>
<td></td>
<td><strong>USD 6000 - Until Jun 02nd 2017</strong></td>
</tr>
</tbody>
</table>

* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr  [ ] Mrs  [ ] Dr  [ ] Miss  [ ] Ms  [ ] Prof
First Name: ________________________  Last Name: ________________________
Email Address: * ________________________
Job Title: ________________________
Organisation: ________________________
Address: ________________________
City: ________________________
Postal / Zip Code: ________________________
Country: ________________________
Phone Number: ________________________
Fax Number: ________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: _______________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World